PTN earnings

Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndromeOnce-weekly injectable MC4R selective peptide agonist remains on track for an IND submission in the fourth quarter of calendar 2026Oral MC4R selective agonist program is advancing, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027Focus is on developing best-in-class MC4R candidates designed to enhance potency, improve t

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -

CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q

Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a

CRANBURY, N.J., Nov. 8, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q1

Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)Patient Dosing Commenced 3Q Calendar Year 2024Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024Topline Results Expected 1Q Calendar Year 2025Dry Eye Disease (DED): PL9643MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical StudiesFDA Confirms Protocols and EndpointsPatient Enrollment Start Expected 1Q Calendar Year 2025Topline Results Anticipated 4Q Calendar Year 2025Potential Partner Collaboration and Funding Discussions OngoingMale Sexual Dysfunction: Bremelanotide Co-Formulated with a PDE5i for the Treatment of Erectile Dysfunction (ED) in Patients That Do Not Resp

Teleconference and Webcast to be held on October 1, 2024 CRANBURY, N.J., Sept. 26, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2024 operating results on Tuesday, October 1, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on October 1, 2024 at 11:00 AM Eastern Time. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for th

CRANBURY, N.J., May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q3 Fiscal Yea

On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025)Multiple Secondary Symptom Endpoints Met, Statistical Significance (P<0.025)On an Intent-to-Treat Analysis, Co-Primary Sign Endpoint and Secondary Sign Endpoints Not MetPL9643 Demonstrated Superiority Over Vehicle in Multiple Sign EndpointsExcellent Safety and Tolerability ProfileFuture Discussions Planned with FDA Regarding Regulatory Approval PathCompany to Host Conference Call at 8:30 a.m. ET TodayCRANBURY, N.J., Feb. 28, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of

CRANBURY, N.J., Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q2

Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients EnrolledTopline Data Expected Late 4Q Calendar Year 2023Interim Analysis of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye Excellent Patient Safety and Tolerability Product ProfilePhase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis  Interim Analysis Targeted for 1Q Calendar Year 2024Topline Results Currently Expected First Half Calendar Year 2024Vyleesi®Net Product Revenue Increased 47% Over the Prior QuarterPrescriptions Dispensed Increased 16% Over the Prior Quarter6 Consecutive Quarters of Double-Di

CRANBURY, N.J., Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 28, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audi

Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL EventAnalysis of Lead-In Population of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye along with Excellent Patient Safety and Tolerability Final Data Expected Second Half Calendar Year 2023Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis  Interim Analysis Targeted for Second Half Calendar Year 2023 Topline Results Currently Expected First Half Calendar Year 2024Vyleesi®Net Product Revenue Increased 16% Over the Prior QuarterPrescriptions Dispensed Increased 27% Over the Prior Quarter5 Consecutive Quarters of Double-Digit Growth

CRANBURY, N.J., May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 16, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q3 Fiscal Year

CRANBURY, N.J., Feb. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

CRANBURY, N.J., Nov. 9, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2022, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast   Q1

Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Sample Size of 350 Patients Topline Results Currently Expected Second Quarter Calendar 2023Vyleesi® - Gross product sales increased 79%, net product revenue increased 257% and prescriptions dispensed increased 49%, over the prior quarterClosed on a $15 Million Private Placement of Redeemable Convertible Preferred StockPatient Recruitment Initiated in a Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis with an Interim Analysis and Topline Results Currently Expected First Half Calendar 2023Teleconference and Webcast to be held on September 22, 2022,

CRANBURY, N.J., Sept. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2022 operating results on Thursday, September 22, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 22, 2022, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audi

Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022Vyleesi® - Gross product sales increased 67%, net product revenue increased 200% and prescriptions dispensed increased 20%, over the prior quarterClosed on a $15 Million Private Placement of Convertible Redeemable Preferred Stock Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Expected to Start Next Month with Topline Results Currently Expected First Quarter Calendar 2023Teleconference and Webcast to be held on May 17, 2022 at 11:00 AM EDTCRANBURY, N.J., May 17, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NY

CRANBURY, N.J., May 11, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 17, 2022, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q3 Fiscal Yea

CRANBURY, N.J., Feb. 15, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced results for its fiscal second quarter ended December 31, 2021. "We are pleased to have initiated a Phase 3 pivotal study of PL9643 in patients with dry eye disease and expect topline results in the second half of calendar year 2022," stated Carl Spana, Ph.D., President and CEO of Palatin. "Regarding Vyleesi,

CRANBURY, N.J., Feb. 10, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter, fiscal year 2022 operating results on Tuesday, February 15, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2022, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q

CRANBURY, N.J., Nov. 15, 2021 /PRNewswire/ -- Palatin Technologies, Inc., (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced results for its first fiscal quarter ended September 30, 2021. "I am excited with the significant advancement of our melanocortin agonist programs and their differentiating product profiles, which include the expected initiation of a Phase 3 pivotal study of PL9643 in patients with dry eye disease next month, and a Phase 2

CRANBURY, N.J., Nov. 10, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its first quarter, fiscal year 2022 operating results on Monday, November 15, 2021, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 15, 2021, at 9:30 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q1 F

CRANBURY, N.J., Sept. 29, 2021 /PRNewswire/ -- Palatin Technologies, Inc., (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced results for its fourth quarter and fiscal year ended June 30, 2021. "During the past year, we worked diligently advancing our lead investigational compound PL9643 through a successful Phase 2 clinical trial, towards a pivotal Phase 3 clinical trial for the treatment of dry eye disease, currently one of the largest markets

CRANBURY, N.J., Sept. 24, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September 29, 2021, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 29, 2021, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Aud

CRANBURY, N.J., May 17, 2021 /PRNewswire/ -- Palatin (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced results for its third fiscal quarter ended March 31, 2021. "I am excited with Palatin's evolution and development advancements utilizing our proprietary melanocortin agonists to treat patients with inflammatory and autoimmune conditions," stated Carl Spana, Ph.D., President and CEO of Palatin. "We are hosting a KOL webinar on May 21st to introd